List of Excipients in Branded Drug SEZABY

Sezaby Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Sezaby is an injectable phenobarbital sodium product developed for the treatment of neonatal seizures. Its commercial opportunity rests less on molecular exclusivity and more on neonatal formulation safety, hospital workflow, regulatory exclusivity, supply reliability, and potential product extensions. The core excipient strategy is deliberately narrow: a lyophilized, preservative-free presentation using mannitol as the principal bulking agent, with pH adjustment as needed.[1]

What is Sezaby and what excipients does it contain?

Sezaby is phenobarbital sodium for injection, supplied as a 100 mg single-dose vial for intravenous or intramuscular administration after reconstitution. The product is indicated for the treatment of neonatal seizures in term and preterm neonates.[1]

The labeled formulation contains:

Component	Function
Phenobarbital sodium	Active pharmaceutical ingredient
Mannitol	Bulking agent and cake-forming excipient for lyophilization
Hydrochloric acid and/or sodium hydroxide	pH adjustment
Sterile Water for Injection	Reconstitution diluent, supplied separately

Sezaby is preservative-free. That characteristic is commercially important because neonates are vulnerable to excipient exposure, and multidose preservative systems can create safety and compatibility concerns in neonatal intensive-care units.

The formulation avoids common excipient categories that can complicate neonatal use, including benzyl alcohol, propylene glycol, parabens, and high-concentration surfactants. The absence of these ingredients can support hospital formulary adoption, although the label does not establish that every avoided excipient would be clinically unacceptable in all neonatal settings.[1]

Why is mannitol used in the Sezaby formulation?

Mannitol is likely used primarily as a lyophilization bulking agent rather than as a pharmacologically active component. It provides solid structure to the freeze-dried cake, supports vial appearance, and can improve handling and reconstitution performance.

For an injectable neonatal product, mannitol offers several formulation advantages:

• It is well established in parenteral products.
• It can produce an acceptable lyophilized cake at relatively modest concentrations.
• It does not require a preservative system in a single-dose vial.
• It can support a low-excipient formulation with limited neonatal exposure.
• It is compatible with a dry-powder presentation that improves long-term stability compared with an aqueous phenobarbital sodium product.

The principal development risks are mannitol crystallization, cake collapse, vial-to-vial variability, reconstitution time, and potential changes in pH or osmolality during storage. These risks must be controlled through the freeze-drying cycle, residual-moisture specification, container-closure system, and reconstitution validation.

What excipient strategy is commercially defensible for Sezaby?

The strongest strategy is a minimal, preservative-free lyophilized formulation supported by tight control of reconstitution and administration parameters.

Formulation priorities

Priority	Commercial rationale
Preservative-free composition	Reduces neonatal excipient concerns and supports single-patient use
Single-dose vial	Fits NICU medication practices and limits contamination risk
Lyophilized product	Improves stability and reduces dependence on cold-chain liquid storage
Fast reconstitution	Reduces medication-preparation time during seizure management
Low residual moisture	Supports shelf life and potency retention
Controlled osmolality	Limits infusion-related tolerability concerns
Low extractables and leachables	Supports neonatal safety and regulatory review
Clear labeling of dilution options	Reduces medication errors and compatibility problems

The most valuable formulation attribute is not the identity of mannitol itself. It is the integrated product design: a stable, ready-to-reconstitute, preservative-free vial that can be used quickly in a NICU without complex compounding.

What formulation patents could protect Sezaby?

Potentially protectable subject matter includes the following:

1. Specific lyophilized compositions containing phenobarbital sodium and mannitol.
2. Defined pH, osmolality, residual-moisture, and reconstitution specifications.
3. Freeze-drying cycles that improve cake integrity or stability.
4. Container-closure systems that limit moisture ingress.
5. Dilution and administration methods for neonatal seizure treatment.
6. Compatibility protocols for infusion systems and commonly used neonatal diluents.
7. Stable liquid or premixed alternatives.
8. Ready-to-use presentations that reduce preparation steps.

The active ingredient itself has been used clinically for decades and does not provide a conventional new-molecule patent position. Commercial protection therefore depends on formulation, manufacturing, method-of-use, orphan-drug exclusivity, and product-specific regulatory protections.

A formulation patent would be strongest if it claimed measurable technical advantages, such as improved stability, reduced reconstitution time, lower impurity formation, or a clinically meaningful reduction in preparation errors. Broad claims covering phenobarbital sodium with a conventional excipient would face greater validity and design-around risk.

When does Sezaby lose exclusivity?

Sezaby received FDA approval in October 2022 for neonatal seizures.[2] The product was granted orphan-drug designation for the neonatal seizure indication. Orphan-drug exclusivity generally lasts seven years from approval, subject to statutory exceptions, placing the principal U.S. orphan-exclusivity period approximately through October 2029.[3]

Orphan exclusivity is indication-specific. It does not create a blanket prohibition on all phenobarbital sodium products. A competing product could potentially enter for a different indication, depending on its labeling and regulatory pathway.

The commercial exclusivity profile should be analyzed separately from patent expiry:

Protection	Relevance to Sezaby
Active-ingredient patent	Limited because phenobarbital is an established compound
Formulation patent	Potentially important if listed and technically narrow
Method-of-use patent	Could protect neonatal seizure treatment claims
Orphan-drug exclusivity	Key protection for the approved neonatal indication
Clinical-investigation exclusivity	May apply depending on the approval basis and FDA exclusivity record
Trade secrets	Relevant to lyophilization, manufacturing controls, and scale-up
Regulatory approval	Supports market access but does not block all competing phenobarbital products

The precise patent term, Orange Book listing status, and any pediatric-exclusivity adjustment require a current FDA Orange Book and regulatory-record review. Patent expiry should not be inferred from the orphan-exclusivity date.

What is the Orange Book status of Sezaby?

Sezaby is an approved prescription drug product under an FDA new drug application. Its Orange Book position, if patent listings are present, would determine whether an ANDA applicant must make a Paragraph IV certification against listed patents.

A generic applicant seeking approval of an equivalent phenobarbital sodium injection could pursue:

• Paragraph I certification if no patent information is listed.
• Paragraph II certification if listed patents have expired.
• Paragraph III certification if the applicant accepts delayed approval until patent expiry.
• Paragraph IV certification if it asserts that listed patents are invalid, unenforceable, or not infringed.

A Paragraph IV notice could trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework, subject to the statutory requirements and litigation timing.[4]

Because phenobarbital sodium injection is an established drug, an ANDA applicant may have a comparatively clear active-ingredient pathway. The principal obstacles would be product-specific formulation differences, dosage-form requirements, bioequivalence or sameness demonstrations, manufacturing controls, and any listed formulation or method-of-use patents.

Which companies could challenge Sezaby?

The likely challenger pool includes manufacturers with existing sterile-injectable infrastructure and phenobarbital products. Potential competitors include:

• Generic injectable manufacturers.
• Hospital injectable specialists.
• Contract manufacturers with lyophilized-vial capacity.
• Companies commercializing neonatal seizure therapies.
• Developers of alternative anticonvulsants, particularly levetiracetam products.

The commercial challenge may not require an exact Sezaby copy. A company could compete through a generic phenobarbital sodium injection, a premixed presentation, a lower-cost vial, or an alternative antiseizure product supported by neonatal clinical data.

An ANDA competitor would likely focus on price and supply reliability. A 505(b)(2) applicant could pursue a differentiated concentration, ready-to-use format, dosing system, or delivery presentation, subject to regulatory requirements and any applicable exclusivity.

What generic entry risks exist for Sezaby?

Generic-entry risk is moderate to high over the long term because the product uses an established active ingredient and serves a concentrated hospital market. The near-term risk is reduced by orphan exclusivity and by the technical demands of sterile neonatal manufacturing.

The main entry scenarios are:

Scenario 1: Existing phenobarbital injection substitution

A lower-priced injectable phenobarbital sodium product could compete for hospital use after relevant regulatory barriers expire. Hospitals may use the generic product for general phenobarbital indications while retaining Sezaby for neonatal protocols.

Scenario 2: Therapeutic substitution

Levetiracetam and other anticonvulsants could compete for neonatal seizure treatment if clinical guidelines, hospital protocols, or comparative evidence shift prescribing practice. The International League Against Epilepsy identifies phenobarbital as an established treatment option, but neonatal seizure management remains clinically sensitive and evidence-driven.[5]

Scenario 3: Product-format competition

A competitor could offer a ready-to-use liquid, pharmacy bulk package, premixed syringe, or automated-dispensing-compatible presentation. These products could compete on preparation time rather than active-ingredient price.

Scenario 4: Supply-driven switching

Sterile injectable shortages can lead hospitals to adopt alternative suppliers rapidly. A reliable competitor with redundant manufacturing capacity could gain share even without a major formulation advantage.

What commercial opportunities exist for Sezaby excipient and dosage-form extensions?

The strongest opportunities are lifecycle products that reduce preparation work or expand use beyond the current vial.

Ready-to-use liquid injection

A stable liquid formulation could eliminate reconstitution. The principal technical challenges would include phenobarbital sodium stability, precipitation control, pH management, container compatibility, and shelf life.

A ready-to-use product could command a premium if it reduces pharmacy labor and medication-preparation errors. Its commercial value would be highest in emergency neonatal settings and hospitals with limited compounding capacity.

Prefilled syringe

A prefilled syringe could standardize dose preparation and reduce vial waste. The main barriers are concentration flexibility, dose accuracy for very small neonates, syringe compatibility, stability, and device approval requirements.

Pharmacy bulk package

A bulk vial could reduce unit cost for high-volume institutions, but it would conflict with the product’s preservative-free positioning unless the package is designed for controlled single-use handling. The neonatal market may favor single-dose packaging despite higher per-dose cost.

Alternative diluent presentation

A dual-chamber vial or integrated diluent system could reduce reconstitution errors. Such a product would require careful evaluation of container-closure integrity, activation force, extractables, and compatibility with neonatal administration systems.

Global presentations

Outside the United States, commercial opportunities include smaller vial sizes, country-specific labeling, and presentations adapted to local neonatal dosing practices. Geographic expansion would require local regulatory review of excipient exposure, stability zones, manufacturing sites, and pharmacopoeial standards.

How strong is the Sezaby patent estate?

The likely estate strength is mixed:

Estate component	Relative strength
Phenobarbital molecule	Weak
General phenobarbital sodium injection	Weak to moderate
Specific lyophilized formulation	Moderate if supported by comparative data
Manufacturing process	Moderate, with trade-secret value
Neonatal method of use	Moderate, subject to claim scope and prior art
Orphan-drug exclusivity	Strong for the approved indication during the exclusivity period
Device or ready-to-use extension	Potentially strong if technically differentiated

The most defensible commercial moat is a combination of orphan exclusivity, clinical adoption, hospital protocols, supply reliability, and execution in sterile manufacturing. A narrow formulation patent alone would be vulnerable to design-around products using a different bulking agent, liquid presentation, concentration, or drying process.

What patent litigation or settlement risk affects Sezaby?

The principal litigation risk would arise if an ANDA applicant files a Paragraph IV certification against a listed formulation or method-of-use patent. Potential outcomes include:

• A patent-infringement action and 30-month stay.
• A settlement with delayed generic entry.
• A covenant not to sue for non-infringing presentations.
• An at-risk launch after litigation or a favorable court ruling.
• Commercial entry after patent expiry but before orphan exclusivity ends for a non-covered indication.

A settlement involving a generic manufacturer could establish an authorized-generic or license arrangement. No specific settlement should be assumed without a filed court record or public company disclosure.

How does Sezaby compare with generic phenobarbital injection?

Factor	Sezaby	Conventional generic phenobarbital injection
Target use	Neonatal seizures	Broader antiseizure and sedative uses
Presentation	Lyophilized single-dose vial	Varies by manufacturer
Preservative strategy	Preservative-free	Product-specific
Reconstitution	Required	Product-specific
Orphan indication protection	Relevant to neonatal seizure indication	May limit labeling depending on exclusivity
Hospital value proposition	Neonatal-specific workflow and labeling	Lower acquisition cost and broader availability
Main competitive advantage	Regulatory positioning and formulation design	Price and supply
Main risk	Generic and therapeutic substitution	Clinical preference and supply constraints

Sezaby’s premium depends on hospitals valuing neonatal-specific labeling, predictable preparation, and formulation controls over the lowest acquisition price.

What revenue exposure does Sezaby create?

Sezaby targets a narrow patient population but an acute-care setting in which hospitals can accept premium pricing for reliable, standardized products. Revenue exposure is concentrated in:

• Neonatal intensive-care units.
• Pediatric hospitals.
• Academic medical centers.
• Emergency neonatal transfer networks.
• Hospital systems with centralized pharmacy operations.

The market is constrained by the relatively small number of neonatal seizure cases, short treatment courses, and the availability of low-cost phenobarbital products. Revenue expansion depends on formulary penetration, international approvals, supply contracts, and lifecycle presentations rather than broad adult-market expansion.

Key Takeaways

• Sezaby is a preservative-free, lyophilized phenobarbital sodium injection for neonatal seizures.
• Mannitol is the principal formulation excipient and functions mainly as a lyophilization bulking agent.
• The commercial value of the formulation lies in stability, reconstitution performance, neonatal suitability, and hospital workflow.
• Orphan-drug exclusivity from the 2022 FDA approval is the most important identifiable near-term regulatory protection.
• Phenobarbital’s established status limits molecule-level patent protection.
• Generic risk is structurally significant because equivalent phenobarbital injection products already exist.
• The most attractive lifecycle opportunities are ready-to-use liquids, prefilled syringes, integrated diluent systems, and international presentations.
• A durable commercial moat requires formulation differentiation, sterile manufacturing reliability, clinical adoption, and hospital protocol integration.

FAQs

Can Sezaby be reformulated without mannitol?

Yes. A competing product could use another bulking agent or a liquid presentation, subject to stability, safety, compatibility, and regulatory requirements. A different excipient system could also reduce the risk of formulation-patent infringement.

Is Sezaby a biologic that faces biosimilar competition?

No. Sezaby is a small-molecule phenobarbital sodium injection. Biosimilar rules do not apply. Competition would arise through generic, 505(b)(2), therapeutic-substitution, or alternative dosage-form pathways.

Could a ready-to-use Sezaby competitor obtain separate market protection?

Potentially. A differentiated ready-to-use product could qualify for patents, regulatory exclusivity, or both, depending on the formulation, indication, clinical evidence, and approval pathway.

Why is a preservative-free formulation important in neonatal care?

It limits exposure to antimicrobial preservatives and supports single-patient dosing. The product still requires controls for sterility, handling, reconstitution, and administration.

What is the largest commercial threat to Sezaby?

The largest long-term threat is substitution by lower-cost phenobarbital injection products or alternative antiseizure medicines. The immediate commercial defense is reliable supply, neonatal-specific labeling, rapid preparation, and adoption in hospital seizure protocols.

References

1. U.S. Food and Drug Administration. (2022). Sezaby (phenobarbital sodium) for injection prescribing information. Sun Pharmaceutical Industries, Inc.

2. U.S. Food and Drug Administration. (2022, October 17). FDA approves first treatment for seizures in newborns. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/orphan-drug-designation-and-exclusivity

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugsatfda

5. Pressler, R. M., Abend, N. S., Auvin, S., Boylan, G., Brigo, F., Vossler, D. G., ... International League Against Epilepsy. (2023). Treatment of seizures in the neonate: Guidelines and consensus recommendations. Epileptic Disorders, 25(3), 1-31.